21:43 uur 02-06-2021

iHealthScreen Inc. kondigt CE-certificering aan voor iPredict ™ geautomatiseerd AI-systeem voor vroege diagnose van diabetische retinopathie (DR), Age Related Macular Degeneration (AMD) en glaucoom-verdachte

iHealthScreen is het eerste bedrijf in de VS om een CE-certificering te ontvangen voor gelijktijdige diagnose van DR-, AMD- en glaucoma-verdachte.

New York- (bedrijfsdraad) – iPredict™ AI Eye Screening System biedt volledig geautomatiseerde diabetische retinopathie (DR), age related macular degeneration (AMD), en glaucoom verdachte screening, inclusief retinale beeldvorming en onmiddellijke rapportage van bruikbare resultaten. Met behulp van het IPREDICT ™ -systeem kunnen de eerstelijnszorg en verschillende speciaal methoden nauwkeurig en efficiënt diabetische patiënten schermen voor DR, Mensen ouder dan 50 voor AMD, en die met een familiegeschiedenis van glaucoom of andere risicofactoren voor vermoedelijke glaucoom.

iHealthScreen Inc. Announces CE Certification for iPredict™ Automated AI System for Early Diagnosis of Diabetic Retinopathy (DR), Age Related Macular Degeneration (AMD), and Glaucoma Suspect

iHealthScreen is the first company in the USA to receive a CE certification for simultaneous diagnosis of DR, AMD, and glaucoma suspect.

NEW YORK–(BUSINESS WIRE)– iPredict AI Eye Screening System provides fully automated diabetic retinopathy (DR), age related macular degeneration (AMD), and glaucoma suspect screening, including retinal imaging, and immediate reporting of actionable results. Using the iPredictSystem, primary care and various specialty practices can accurately and efficiently screen diabetic patients for DR, people over 50 for AMD, and those with a family history of glaucoma or other risk factors for suspected glaucoma.

Once high-resolution images of the patient’s eyes have been captured using a color fundus camera and submitted to the iPredict AI System, the screening results are available in a fully automated report in less than 60 seconds. The entire test can easily and reliably be completed within 5 minutes.

iPredict’s CE certification indications for use as follows:

  • iPredict-DR can detect more than mild DR or vision threatening DR such as severe non-Proliferative DR, proliferative and diabetic macular EDEMA.
  • iPredict-AMD can detect referable AMD such as intermediate to late AMD and non-referable AMD such as early or none.
  • iPredict-glaucoma detects glaucoma suspects based on abnormal optic discs.

If referable stage disease is detected for any of these conditions, the iPredict automated report recommends a visit to an Ophthalmologist for appropriate treatment. Otherwise, in accordance with standards of care, a follow up visit in one year is suggested.

iPredict is indicated for use by healthcare providers in clinics, hospitals or other healthcare facilities to automatically detect DR, AMD and glaucoma suspect.

“This technology could be particularly useful in identifying someone who has slipped across the boundary to progress into severity,” Dr. Theodore Smith (Professor in Ophthalmology and Neuroscience at Icahn School of Medicine at Mount Sinai, New York) said.

“This is a major milestone for iHealthScreen. iPredict eye disease diagnostic tools will help prevent blindness for millions of people and save insurers countless millions of dollars in avoidable healthcare cost,” said Dr. Alauddin Bhuiyan, the founder and CEO of the company.

iHealthScreen company is open to partnership within its products. For more information: https://www.iHealthScreen.org

Contacts

Alauddin Bhuiyan, Ph.D.

CEO, iHealthScreen Inc.

E: bhuiyan@ihealthscreen.org
T: +1 718 926 9000

Check out our twitter: @NewsNovumpr